162 related articles for article (PubMed ID: 34010146)
21. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
22. The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Wang W; Liu L; Yu X
J Neuroendocrinol; 2022 Jun; 34(6):e13112. PubMed ID: 35380016
[TBL] [Abstract][Full Text] [Related]
23. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
Chatzellis E; Angelousi A; Daskalakis K; Tsoli M; Alexandraki KI; Wachuła E; Meirovitz A; Maimon O; Grozinsky-Glasberg S; Gross D; Kos-Kudła B; Koumarianou A; Kaltsas G
Neuroendocrinology; 2019; 109(4):333-345. PubMed ID: 31167197
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
25. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study.
Ballal S; Yadav MP; Damle NA; Sahoo RK; Bal C
Clin Nucl Med; 2017 Nov; 42(11):e457-e466. PubMed ID: 28872545
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Squires MH; Worth PJ; Konda B; Shah MH; Dillhoff ME; Abdel-Misih S; Norton JA; Visser BC; Dua M; Pawlik TM; Schmidt CR; Poultsides G; Cloyd JM
Pancreas; 2020 Mar; 49(3):355-360. PubMed ID: 32132509
[TBL] [Abstract][Full Text] [Related]
27.
Paganelli G; Sansovini M; Nicolini S; Grassi I; Ibrahim T; Amadori E; Di Iorio V; Monti M; Scarpi E; Bongiovanni A; Altini M; Urso L; Cittanti C; Matteucci F; Severi S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):152-160. PubMed ID: 32472437
[TBL] [Abstract][Full Text] [Related]
28. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
29. Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms.
Melhorn P; Mazal P; Wolff L; Popov P; Kretschmer-Chott E; Haug A; Mayerhoefer ME; Raderer M; Kiesewetter B
Endocr Relat Cancer; 2024 Mar; 31(3):. PubMed ID: 38214923
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
[TBL] [Abstract][Full Text] [Related]
31. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L
Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077
[TBL] [Abstract][Full Text] [Related]
32. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study.
Jeong H; Shin J; Jeong JH; Kim KP; Hong SM; Kim YI; Ryu JS; Ryoo BY; Yoo C
ESMO Open; 2021 Jun; 6(3):100119. PubMed ID: 33901869
[TBL] [Abstract][Full Text] [Related]
33. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
Kwekkeboom DJ; de Herder WW; Kam BL; van Eijck CH; van Essen M; Kooij PP; Feelders RA; van Aken MO; Krenning EP
J Clin Oncol; 2008 May; 26(13):2124-30. PubMed ID: 18445841
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
Ünal Ç; Azizy A; Karabulut S; Taştekin D; Akyıldız A; Yaşar S; Yalçın Ş; Çoban E; Evrensel T; Kalkan Z; Oruç Z; Derin S; Turna ZH; Bayram D; Köş FT; Şendur MAN; Sever N; Ercelep Ö; Seyyar M; Kefeli U; Uygun K; Özçelik M; Ön S; Şanlı UA; Canaslan K; Ünek İT; Yücel KB; Özdemir N; Yazıcı O; Güzel HG; Salim DK; Göksu SS; Tatlı AM; Ordu Ç; Selvi O; Sakin A; Büyükbayram ME; Dursun B; Ürün Y; Arak H; Ağdaş G; Uğraklı M; Hendem E; Eryılmaz MK; Bilgin B; Topçu A; Şimşek M; Büyükşimşek M; Akay B; Erdal GŞ; Karataş F; Alan Ö; Çağlayan M; Kahvecioğlu FA; Demirci A; Paksoy N; Çetin B; Gümüş M; Ak N; Aydınalp Y; Paydaş S; Güven DC; Kılıçkap S; Sağlam S
Oncologist; 2023 Oct; 28(10):875-884. PubMed ID: 37676712
[TBL] [Abstract][Full Text] [Related]
35. 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants.
Fröss-Baron K; Garske-Roman U; Welin S; Granberg D; Eriksson B; Khan T; Sandström M; Sundin A
Neuroendocrinology; 2021; 111(4):330-343. PubMed ID: 32097917
[TBL] [Abstract][Full Text] [Related]
36. [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.
Swärd C; Bernhardt P; Ahlman H; Wängberg B; Forssell-Aronsson E; Larsson M; Svensson J; Rossi-Norrlund R; Kölby L
World J Surg; 2010 Jun; 34(6):1368-72. PubMed ID: 20066413
[TBL] [Abstract][Full Text] [Related]
37. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours.
Sabet A; Haslerud T; Pape UF; Sabet A; Ahmadzadehfar H; Grünwald F; Guhlke S; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):205-10. PubMed ID: 24030668
[TBL] [Abstract][Full Text] [Related]
38. Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.
Dogan I; Tastekin D; Karabulut S; Sakar B
J Dig Dis; 2022 Aug; 23(8-9):493-499. PubMed ID: 36081250
[TBL] [Abstract][Full Text] [Related]
39. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz PL; Graham NT; Catalano PJ; Nimeiri HS; Fisher GA; Longacre TA; Suarez CJ; Martin BA; Yao JC; Kulke MH; Hendifar AE; Shanks JC; Shah MH; Zalupski MM; Schmulbach EL; Reidy-Lagunes DL; Strosberg JR; O'Dwyer PJ; Benson AB
J Clin Oncol; 2023 Mar; 41(7):1359-1369. PubMed ID: 36260828
[TBL] [Abstract][Full Text] [Related]
40. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
